Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Debt (2019 - 2026)

Akebia Therapeutics has reported Non-Current Debt over the past 7 years, most recently at $48.2 million for Q4 2025.

  • Quarterly Non-Current Debt rose 24.7% to $48.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.2 million through Dec 2025, up 24.7% year-over-year, with the annual reading at $48.2 million for FY2025, 24.7% up from the prior year.
  • Non-Current Debt was $48.2 million for Q4 2025 at Akebia Therapeutics, up from $47.6 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $97.2 million in Q3 2021 and troughed at $17.2 million in Q4 2023.
  • The 5-year median for Non-Current Debt is $38.5 million (2024), against an average of $47.3 million.
  • Year-over-year, Non-Current Debt tumbled 49.58% in 2023 and then surged 125.18% in 2024.
  • A 5-year view of Non-Current Debt shows it stood at $97.2 million in 2021, then crashed by 64.95% to $34.1 million in 2022, then tumbled by 49.58% to $17.2 million in 2023, then skyrocketed by 125.18% to $38.7 million in 2024, then increased by 24.7% to $48.2 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Non-Current Debt are $48.2 million (Q4 2025), $47.6 million (Q3 2025), and $47.1 million (Q2 2025).